Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer

被引：0
|
作者：
Miano, S. T. [1 ]
Rossi, G. [1 ]
Marsili, S. [1 ]
Petrioli, R. [1 ]
Pascucci, A. [1 ]
Francini, G. [1 ]
机构：
[1] Uoc Oncol Med Scotte, Siena, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A67
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [1] Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer
    Kwa, Maryann J.
    Iwano, Alyssa
    Esteva, Francisco J.
    Novik, Yelena
    Speyer, James L.
    Oratz, Ruth
    Meyers, Marleen Iva
    Axelrod, Deborah M.
    Hogan, Rebecca
    Mendoza, Sandra
    Goldberg, Judith D.
    Muggia, Franco
    Adams, Sylvia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer
    Ho, I. -Wei
    Tseng, Yi-Ru
    Liu, Chun-Yu
    Tsai, Yi-Fang
    Huang, Chi-Cheng
    Tseng, Ling-Ming
    Chao, Ta-Chung
    Lai, Jiun-, I
    JOURNAL OF CANCER, 2025, 16 (05): : 1726 - 1735
  • [3] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Lobo, Christopher
    Lopes, Gilberto
    Baez, Odalys
    Castrellon, Aurelio
    Ferrell, Annapoorna
    Higgins, Connie
    Hurley, Erin
    Hurley, Judith
    Reis, Isildinha
    Richman, Stephen
    Seo, Pearl
    Silva, Orlando
    Slingerland, Joyce
    Tukia, Keleni
    Welsh, Catherine
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
  • [5] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Christopher Lobo
    Gilberto Lopes
    Odalys Baez
    Aurelio Castrellon
    Annapoorna Ferrell
    Connie Higgins
    Erin Hurley
    Judith Hurley
    Isildinha Reis
    Stephen Richman
    Pearl Seo
    Orlando Silva
    Joyce Slingerland
    Keleni Tukia
    Catherine Welsh
    Stefan Glück
    Breast Cancer Research and Treatment, 2010, 123 : 427 - 435
  • [6] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
  • [7] Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer
    Sakaguchi, Koichi
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    ANTICANCER RESEARCH, 2016, 36 (12) : 6515 - 6519
  • [8] Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer
    Glueck, S.
    Lobo, C.
    Lopes, G.
    Castrellon, A.
    Hurley, J.
    Reis, I.
    Richman, S.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    EJC SUPPLEMENTS, 2010, 8 (03): : 196 - 196
  • [9] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
  • [10] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Tamura, Kenji
    Inoue, Kenichi
    Masuda, Norikazu
    Takao, Shintaro
    Kashiwaba, Masahiro
    Tokuda, Yutaka
    Iwata, Hiroji
    Yamamoto, Naohito
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakayama, Takahiro
    Sato, Nobuaki
    Toyama, Tatsuya
    Ishida, Takanori
    Arioka, Hitoshi
    Saito, Mitsue
    Ohno, Shinji
    Yamauchi, Hideko
    Yamada, Kimito
    Watanabe, Junichiro
    Ishiguro, Hiroshi
    Fujiwara, Yasuhiro
    CANCER SCIENCE, 2017, 108 (05): : 987 - 994
12345